The Lee’s Summit, Mo., lab signed an agreement with Ithaca, N.Y.-based Cornell University to commercialize the blood test, according to the March 28 report. Instead of a biopsy, physicians can use the test to look at circulating cell-free DNA, which indicates organ damage.
The test can narrow organ damage down to tissue and cell type, which other cell-free DNA tests struggle to do. Targeting the damage helps physicians identify whether a COVID-19 patient is suffering muscle breakdown due to being bedridden or a more serious issue, like lung damage.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
